PDF(Pubmed)
Abstract：
Bone is a dynamic tissue. It remodels, preserving serum calcium, repairing microdamage, and maintaining strength. Osteoporosis is caused by a decrease in bone strength, which manifests clinically as low-energy vertebral and non-vertebral fractures. Osteoporosis poses a significant public health challenge. While it\'s often portrayed as primarily impacting postmenopausal women, there\'s been growing recognition among researchers and clinicians regarding its prevalence in men. Major fracture in men has higher mortality rates than in women. Denosumab is a fully human monoclonal immunoglobulin G2 (IgG2) antibody that binds to RANKL, the principal regulator of osteoclastic bone resorption. Multiple studies suggest that denosumab is both effective and safe, exhibiting higher adherence rates and greater patient satisfaction. In this narrative review, we highlighted the effects of denosumab in men with osteoporosis, subsequent changes in bone mineral density, and bone turnover markers outlining the literature and guideline support.
摘要：
骨是动态组织。它改造，保持血清钙，修复微损伤，保持力量。骨质疏松是由骨强度下降引起的，在临床上表现为低能量椎骨和非椎骨骨折。骨质疏松症构成了重大的公共卫生挑战。虽然它通常被描述为主要影响绝经后妇女，研究人员和临床医生越来越认识到它在男性中的患病率。男性严重骨折的死亡率高于女性。Denosumab是一种与RANKL结合的完全人单克隆免疫球蛋白G2（IgG2）抗体，破骨细胞骨吸收的主要调节剂。多项研究表明，denosumab既有效又安全，表现出更高的依从率和更高的患者满意度。在这篇叙述性评论中，我们强调了denosumab对男性骨质疏松症的影响，随后骨矿物质密度的变化，骨转换标记概述了文献和指南支持。
